Key Points
- Insider Hanlin Gao sold 939 shares of Fulgent Genetics at an average price of $19.91, totaling $18,695.49. The sale covered tax-withholding obligations tied to vested equity awards, leaving Gao with 987,790 shares.
- Fulgent Genetics reported quarterly revenue of $85.39 million and an EPS loss of $0.58, missing analyst estimates for both revenue and earnings. The company maintains negative profitability metrics and guided fiscal 2026 EPS to between -$2.35 and -$2.22.
- Analyst sentiment remains cautious, with an overall “Hold” rating and a consensus price target of $27.50. The stock recently traded near $19.61, while institutional investors and hedge funds collectively own 48.06% of the company.
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 939 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $19.91, for a total value of $18,695.49. Following the completion of the sale, the insider owned 987,790 shares in the company, valued at $19,666,898.90. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Hanlin Gao also recently made the following trade(s):
- On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The shares were sold at an average price of $17.89, for a total transaction of $30,198.32.
Fulgent Genetics Stock Performance
Fulgent Genetics stock opened at $19.61 on Friday. The firm has a market cap of $539.47 million, a price-to-earnings ratio of -6.95 and a beta of 0.90. Fulgent Genetics, Inc. has a 52-week low of $13.46 and a 52-week high of $31.04. The firm has a 50 day moving average price of $19.63 and a two-hundred day moving average price of $18.15.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The firm had revenue of $85.39 million during the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350--2.220 EPS. As a group, equities research analysts predict that Fulgent Genetics, Inc. will post -3.48 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on FLGT. Wall Street Zen raised shares of Fulgent Genetics from a "strong sell" rating to a "sell" rating in a research report on Saturday. Weiss Ratings raised Fulgent Genetics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday. Finally, Piper Sandler upped their target price on Fulgent Genetics from $15.00 to $19.00 and gave the company a "neutral" rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $27.50.
Read Our Latest Analysis on FLGT
Institutional Trading of Fulgent Genetics
Large investors have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Fulgent Genetics in the 2nd quarter valued at $25,000. Farther Finance Advisors LLC boosted its stake in Fulgent Genetics by 69.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company's stock worth $35,000 after acquiring an additional 548 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Fulgent Genetics during the fourth quarter worth $35,000. Legal & General Group Plc bought a new position in Fulgent Genetics during the second quarter worth $38,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company's stock worth $48,000 after purchasing an additional 1,251 shares during the period. Institutional investors and hedge funds own 48.06% of the company's stock.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company's infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.
Fulgent's product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
